Update Mammakarzinom 2023 Teil 1 – Brustkrebs in frühen Krankheitsstadien

Zusammenfassung

Mit den Zulassungen von Abemaciclib (monarchE-Studie) und Olaparib (OlympiA-Studie) in der adjuvanten Therapiesituation haben sich die Therapiestandards bei der Behandlung von Patientinnen mit Mammakarzinom in Frühstadien seit Langem deutlich verändert. Somit übertragen sich einige vielfältige Entwicklungen aus der metastasierten Therapiesituation langsam in die adjuvante. Kürzlich ist auch die NATALEE-Studie als positiv berichtet worden.

Weitere Therapiestudien mit Substanzen, die in der metastasierten Situation etabliert sind, werden zurzeit durchgeführt. Dies sind z. B. die DESTINY Breast05-Studie mit Trastuzumab-Deruxtecan und die SASCIA-Studie mit Sacituzumab Govitecan.

In dieser Übersichtsarbeit werden die neuesten Entwicklungen der letzten Monate zusammengefasst und in den jeweiligen Kontext eingeordnet.

Schlüsselwörter

Brustkrebs - Frühstadium - adjuvante Therapie - neoadjuvante Therapie - endokrine Therapie - Biomarker

Publication History

Received: 12 April 2023

Accepted: 13 April 2023

Article published online:
06 June 2023

• References/Literatur

• 1 Lopes Cardozo JMN, Andrulis IL, Bojesen SE. et al. Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival. J Clin Oncol 2023; 41: 1849-1863 DOI: 10.1200/JCO.22.01978.
• 2 DeVries AA, Dennis J, Tyrer JP. et al. Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci. J Natl Cancer Inst 2022; 114: 1533-1544 DOI: 10.1093/jnci/djac160. (PMID: 36210504)
• 3 Ruth KS, Day FR, Hussain J. et al. Genetic insights into biological mechanisms governing human ovarian ageing. Nature 2021; 596: 393-397 DOI: 10.1038/s41586-021-03779-7.
• 4 Kapoor PM, Mavaddat N, Choudhury PP. et al. Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. J Natl Cancer Inst 2021; 113: 329-337 DOI: 10.1093/jnci/djaa056.
• 5 Dorling L, Carvalho S, Allen J. Breast Cancer Association Consortium. et al. Breast Cancer Risk Genes – Association Analysis in More than 113,000 Women. N Engl J Med 2021; 384: 428-439 DOI: 10.1056/NEJMoa1913948. (PMID: 30267249)
• 6 Fachal L, Aschard H, Beesley J. et al. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nat Genet 2020; DOI: 10.1038/s41588-019-0537-1. (PMID: 31911677)
• 7 Dorling L, Carvalho S, Allen J. et al. Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Med 2022; 14: 51 DOI: 10.1186/s13073-022-01052-8. (PMID: 35585550)
• 8 Vachon CM, Scott CG, Tamimi RM. et al. Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk. Breast Cancer Res 2019; 21: 68 DOI: 10.1186/s13058-019-1138-8.
• 9 Wu L, Shi W, Long J. et al. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nat Genet 2018; 50: 968-978 DOI: 10.1038/s41588-018-0132-x. (PMID: 29915430)
• 10 Mavaddat N, Michailidou K, Dennis J. et al. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Am J Hum Genet 2019; 104: 21-34 DOI: 10.1016/j.ajhg.2018.11.002. (PMID: 30554720)
• 11 Milne RL, Kuchenbaecker KB, Michailidou K. et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet 2017; 49: 1767-1778 DOI: 10.1038/ng.3785.
• 12 Michailidou K, Lindstrom S, Dennis J. et al. Association analysis identifies 65 new breast cancer risk loci. Nature 2017; 551: 92-94 DOI: 10.1038/nature24284. (PMID: 29059683)
• 13 Day FR, Thompson DJ, Helgason H. et al. Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. Nat Genet 2017; 49: 834-841 DOI: 10.1038/ng.3841.
• 14 Vachon CM, Pankratz VS, Scott CG. et al. The contributions of breast density and common genetic variation to breast cancer risk. J Natl Cancer Inst 2015; 107: dju397 DOI: 10.1093/jnci/dju397. (PMID: 25745020)
• 15 Rudolph A, Fasching PA, Behrens S. et al. A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density. Breast Cancer Res 2015; 17: 110 DOI: 10.1186/s13058-015-0625-9.
• 16 Michailidou K, Beesley J, Lindstrom S. et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet 2015; 47: 373-380 DOI: 10.1038/ng.3242.
• 17 Mavaddat N, Pharoah PD, Michailidou K. et al. Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst 2015; 107: djv036 DOI: 10.1093/jnci/djv036.
• 18 Day FR, Ruth KS, Thompson DJ. et al. Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nat Genet 2015; 47: 1294-1303 DOI: 10.1038/ng.3412. (PMID: 26414677)
• 19 Pharoah PD, Tsai YY, Ramus SJ. et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 2013; 45: 362-370 DOI: 10.1038/ng.2564. (PMID: 23535730)
• 20 Michailidou K, Hall P, Gonzalez-Neira A. et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 2013; 45: 353-361 DOI: 10.1038/ng.2563.
• 21 Garcia-Closas M, Couch FJ, Lindstrom S. et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet 2013; 45: 392-398 DOI: 10.1038/ng.2561. (PMID: 23535733)
• 22 Bojesen SE, Pooley KA, Johnatty SE. et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 2013; 45: 371-384 DOI: 10.1038/ng.2566.
• 23 Vachon CM, Scott CG, Fasching PA. et al. Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk. Cancer Epidemiol Biomarkers Prev 2012; 21: 1156-1166 DOI: 10.1158/1055-9965.EPI-12-0066.
• 24 Ghoussaini M, Fletcher O, Michailidou K. et al. Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 2012; 44: 312-318 DOI: 10.1038/ng.1049. (PMID: 22267197)
• 25 Haiman CA, Chen GK, Vachon CM. et al. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet 2011; 43: 1210-1214 DOI: 10.1038/ng.985.
• 26 Antoniou AC, Wang X, Fredericksen ZS. et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 2010; 42: 885-892 DOI: 10.1038/ng.669.
• 27 Wunderle M, Olmes G, Nabieva N. et al. Risk, Prediction and Prevention of Hereditary Breast Cancer – Large-Scale Genomic Studies in Times of Big and Smart Data. Geburtshilfe Frauenheilkd 2018; 78: 481-492 DOI: 10.1055/a-0603-4350. (PMID: 29880983)
• 28 Chen H, Fan S, Stone J. et al. Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci. Breast Cancer Res 2022; 24: 27 DOI: 10.1186/s13058-022-01524-0. (PMID: 35414113)
• 29 Lindstrom S, Thompson DJ, Paterson AD. et al. Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. Nat Commun 2014; 5: 5303 DOI: 10.1038/ncomms6303.
• 30 Lindstrom S, Thompson DJ, Paterson AD. et al. Corrigendum: genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. Nat Commun 2015; 6: 8358 DOI: 10.1038/ncomms9358.
• 31 Rudolph A, Song M, Brook MN. et al. Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium. Int J Epidemiol 2018; 47: 526-536 DOI: 10.1093/ije/dyx242. (PMID: 29315403)
• 32 Brouckaert O, Rudolph A, Laenen A. et al. Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. Breast Cancer Res 2017; 19: 119 DOI: 10.1186/s13058-017-0909-3. (PMID: 29116004)
• 33 Barrdahl M, Rudolph A, Hopper JL. et al. Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. Int J Cancer 2017; 141: 1830-1840 DOI: 10.1002/ijc.30859.
• 34 Ye ZF, Li S, Dite GS. et al. Weight is More Informative than Body Mass Index for Predicting Postmenopausal Breast Cancer Risk: Prospective Family Study Cohort (ProF-SC). Cancer Prev Res 2022; 15: 8 DOI: 10.1158/1940-6207.Capr-21-0164.
• 35 Pegington M, Harkness EF, Howell A. et al. Magnitude and attributed reasons for adult weight gain amongst women at increased risk of breast cancer. BMC Womens Health 2022; 22: 11 DOI: 10.1186/s12905-022-02037-w. (PMID: 36371176)
• 36 Niehoff NM, Terry MB, Bookwalter DB. et al. Air Pollution and Breast Cancer: An Examination of Modification By Underlying Familial Breast Cancer Risk. Cancer Epidemiol Biomarkers Prev 2022; 31: 422-429 DOI: 10.1158/1055-9965.Epi-21-1140. (PMID: 34906967)
• 37 Naaman SC, Shen S, Zeytinoglu M. et al. Obesity and Breast Cancer Risk: The Oncogenic Implications of Metabolic Dysregulation. J Clin Endocrinol Metab 2022; 107: 2154-2166 DOI: 10.1210/clinem/dgac241. (PMID: 35453151)
• 38 Kresovich JK, Xu ZL, O’Brien KM. et al. Blood DNA methylation profiles improve breast cancer prediction. Mol Oncol 2022; 16: 42-53 DOI: 10.1002/1878-0261.13087. (PMID: 34411412)
• 39 Geldhof V, de Rooij L, Sokol L. et al. Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast. Nat Commun 2022; 13: 19 DOI: 10.1038/s41467-022-33052-y. (PMID: 36127427)
• 40 Smith SG, Sestak I, Morris MA. et al. The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies. Breast Cancer Res Tr 2021; 188: 215-223 DOI: 10.1007/s10549-021-06141-7.
• 41 Oh H, Wild RA, Manson JE. et al. Obesity, Height, and Serum Androgen Metabolism among Postmenopausal Women in the Women’s Health Initiative Observational Study. Cancer Epidemiol Biomarkers Prev 2021; 30: 2018-2029 DOI: 10.1158/1055-9965.Epi-21-0604.
• 42 Mubarik S, Liu XX, Malik SS. et al. Evaluation of lifestyle risk factor differences in global patterns of breast cancer mortality and DALYs during 1990–2017 using hierarchical age-period-cohort analysis. Environ Sci Pollut Res 2021; 28: 49864-49876 DOI: 10.1007/s11356-021-14165-1.
• 43 Masala G, Palli D, Ermini I. et al. The DAMA25 Study: Feasibility of a Lifestyle Intervention Programme for Cancer Risk Reduction in Young Italian Women with Breast Cancer Family History. Int J Environ Res Public Health 2021; 18: 13 DOI: 10.3390/ijerph182312287.
• 44 Lukasiewicz S, Czeczelewski M, Forma A. et al. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers 2021; 13: 30 DOI: 10.3390/cancers13174287. (PMID: 34503097)
• 45 Kapoor PM, Mavaddat N, Choudhury PP. et al. Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. J Natl Cancer Inst 2021; 113: 329-337 DOI: 10.1093/jnci/djaa056.
• 46 Houghton LC, Howland RE, Wei Y. et al. The Steroid Metabolome and Breast Cancer Risk in Women with a Family History of Breast Cancer: The Novel Role of Adrenal Androgens and Glucocorticoids. Cancer Epidemiol Biomarkers Prev 2021; 30: 89-96 DOI: 10.1158/1055-9965.Epi-20-0471.
• 47 Daly AA, Rolph R, Cutress RI. et al. A Review of Modifiable Risk Factors in Young Women for the Prevention of Breast Cancer. Breast Cancer (Dove Med Press) 2021; 13: 241-257 DOI: 10.2147/BCTT.S268401. (PMID: 33883932)
• 48 Hopper JL, Dite GS, MacInnis RJ. et al. Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC). Breast Cancer Res 2018; 20: 132 DOI: 10.1186/s13058-018-1056-1. (PMID: 30390716)
• 49 Bhardwaj P, Iyengar NM, Zahid H. et al. Obesity promotes breast epithelium DNA damage in women carrying a germline mutation in BRCA1 or BRCA2. Sci Transl Med 2023; 15: eade1857 DOI: 10.1126/scitranslmed.ade1857. (PMID: 36812344)
• 50 Marra A, Gazzo A, Gupta A. et al. Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC). Ann Oncol 2022; 33 (Suppl. 7) S88-S121 DOI: 10.1016/annonc/annonc1089.
• 51 Barone I, Caruso A, Gelsomino L. et al. Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives. Obes Rev 2022; 23: e13358 DOI: 10.1111/obr.13358. (PMID: 34559450)
• 52 Yadav S, Boddicker NJ, Na J. et al. Abstract GS4–04: Population-based estimates of contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. San Antonio Breast Cancer Symposium 2022. Cancer Res 2023; 83 (Suppl. 5) GS4–04 DOI: 10.1158/1538-7445.SABCS22-GS4-04.
• 53 Shimelis H, LaDuca H, Hu C. et al. Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. J Natl Cancer Inst 2018; 110: 855-862 DOI: 10.1093/jnci/djy106. (PMID: 30099541)
• 54 Hoyer J, Vasileiou G, Uebe S. et al. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria. BMC Cancer 2018; 18: 926 DOI: 10.1186/s12885-018-4821-8. (PMID: 30257646)
• 55 Harbeck N, Rastogi P, Martin M. et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol 2021; 32: 1571-1581 DOI: 10.1016/j.annonc.2021.09.015.
• 56 Johnston SRD, Harbeck N, Hegg R. et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol 2020; 38: 3987-3998 DOI: 10.1200/JCO.20.02514.
• 57 Johnston SRD, Toi M, O’Shaughnessy J. et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2023; 24: 77-90 DOI: 10.1016/S1470-2045(22)00694-5.
• 58 United States Food and Drug Administration (FDA). FDA expands early breast cancer indication for abemaciclib with endocrine therapy. 2023 Accessed April 03, 2023 at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-early-breast-cancer-indication-abemaciclib-endocrine-therapy
• 59 Johnston SRD, Andre V. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer – Authors’ reply. Lancet Oncol 2023; 24: e104 DOI: 10.1016/S1470-2045(23)00065-7. (PMID: 36858725)
• 60 Translational Research in Oncology. NATALEE (TRIO033) Phase III trial demonstrates ribociclib significantly reduces the risk of recurrence for patients with early breast cancer, at interim analysis. 2023 Accessed April 05, 2023 at: https://www.trioncology.org/news/natalee-trio033-phase-iii-trial-demonstrates-ribociclib-significantly-reduces-the-risk-of-recurrence-for-patients-with-early-breast-cancer-at-interim-analysis/
• 61 clinicaltrials.gov. NCT03701334. A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2− Early Breast Cancer (NATALEE). NIH US National Library of Medicine; 2018. Accessed November 07, 2020 at: https://clinicaltrials.gov/ct2/show/NCT03701334
• 62 Slamon DJ, Fasching PA, Patel R. et al. NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC). J Clin Oncol 2019; 37: TPS597 DOI: 10.1200/JCO.2019.37.15_suppl.TPS597.
• 63 Novartis. Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer. 2023 Accessed April 03, 2023 at: https://www.novartis.com/news/media-releases/novartis-kisqali-phase-iii-natalee-trial-meets-primary-endpoint-interim-analysis-demonstrating-clinically-meaningful-benefit-broad-population-patients-early-breast-cancer
• 64 Fasching PA. Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?. Lancet Oncol 2018; 19: 150-151 DOI: 10.1016/S1470-2045(18)30008-1. (PMID: 29337093)
• 65 Copson ER, Maishman TC, Tapper WJ. et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol 2018; 19: 169-180 DOI: 10.1016/S1470-2045(17)30891-4. (PMID: 29337092)
• 66 Partridge AH, Niman SM, Ruggeri M. et al. Abstract GS4–09: Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48–14/BIG 8–13). San Antonio Breast Cancer Symposium 2022. Cancer Res 2023; 83 (Suppl. 5) GS4–09 DOI: 10.1158/1538-7445.SABCS22-GS4-09.
• 67 Pagani O, Walley BA, Fleming GF. et al. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. J Clin Oncol 2023; 41: 1376-1382 DOI: 10.1200/JCO.22.01064.
• 68 Geyer Jr. CE, Garber JE, Gelber RD. et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol 2022; 33: 1250-1268 DOI: 10.1016/j.annonc.2022.09.159.
• 69 Tung NM, Robson ME, Ventz S. et al. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol 2020; 38: 4274-4282 DOI: 10.1200/JCO.20.02151. (PMID: 33119476)
• 70 Ngoi NYL, Tan DSP. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?. ESMO Open 2021; 6: 100144 DOI: 10.1016/j.esmoop.2021.100144. (PMID: 34015643)
• 71 Fasching PA, Link T, Hauke J. et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol 2021; 32: 49-57 DOI: 10.1016/j.annonc.2020.10.471.
• 72 Fasching PA, Schmatloch S, Hauke J. et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative early breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study. San Antonio Breast Cancer Symposium 2022. Cancer Res 2023; 83 (Suppl. 5) GS5–02 DOI: 10.1158/1538-7445.SABCS22-GS5-02.
• 73 Sparano JA, Gray RJ, Makower DF. et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2018; 379: 111-121 DOI: 10.1056/NEJMoa1804710. (PMID: 29860917)
• 74 Sparano JA, Gray RJ, Makower DF. et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2015; 373: 2005-2014 DOI: 10.1056/NEJMoa1510764. (PMID: 26412349)
• 75 Jonat W, Kaufmann M, Sauerbrei W. et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002; 20: 4628-4635 DOI: 10.1200/JCO.2002.05.042.
• 76 Ruddy KJ, Schaid DJ, Partridge AH. et al. Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer. Fertil Steril 2019; 112: 731-739.e1 DOI: 10.1016/j.fertnstert.2019.05.018.
• 77 Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006; 24: 5769-5779 DOI: 10.1200/JCO.2006.07.2793. (PMID: 17130515)
• 78 Pagani O, O’Neill A, Castiglione M. et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 1998; 34: 632-640 DOI: 10.1016/s0959-8049(97)10036-3.
• 79 Francis PA. Role of Ovarian Suppression in Early Premenopausal Breast Cancer. Hematol Oncol Clin North Am 2023; 37: 79-88 DOI: 10.1016/j.hoc.2022.08.006. (PMID: 36435615)
• 80 Sparano J, Gray RJ, Makower D. et al. Abstract GS1–05: Trial Assigning Individualized Options for Treatment (TAILORx): An update including 12-year event rates. San Antonio Breast Cancer Symposium 2022. Cancer Res 2023; 83 (Suppl. 5) GS1–05 DOI: 10.1158/1538-7445.SABCS22-GS1-05.
• 81 Karadal B, Kim G, Sharma V. et al. Abstract GS1–02: Racial Disparity in Tumor Microenvironment and Outcomes in Residual Breast Cancer Treated with Neoadjuvant Chemotherapy. San Antonio Breast Cancer Symposium 2022. Cancer Res 2023; 83 (Suppl. 5) GS1–02 DOI: 10.1158/1538-7445.SABCS22-GS1-02.
• 82 Roh-Johnson M, Bravo-Cordero JJ, Patsialou A. et al. Macrophage contact induces RhoA GTPase signaling to trigger tumor cell intravasation. Oncogene 2014; 33: 4203-4212 DOI: 10.1038/onc.2013.377. (PMID: 24056963)
• 83 Wyckoff JB, Wang Y, Lin EY. et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 2007; 67: 2649-2656 DOI: 10.1158/0008-5472.CAN-06-1823. (PMID: 17363585)
• 84 Harney AS, Arwert EN, Entenberg D. et al. Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2hi Macrophage-Derived VEGFA. Cancer Discov 2015; 5: 932-943 DOI: 10.1158/2159-8290.CD-15-0012. (PMID: 26269515)
• 85 Robinson BD, Sica GL, Liu YF. et al. Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin Cancer Res 2009; 15: 2433-2441 DOI: 10.1158/1078-0432.CCR-08-2179. (PMID: 19318480)
• 86 Karagiannis GS, Condeelis JS, Oktay MH. Chemotherapy-induced metastasis: mechanisms and translational opportunities. Clin Exp Metastasis 2018; 35: 269-284 DOI: 10.1007/s10585-017-9870-x. (PMID: 29307118)
• 87 Rohan TE, Xue X, Lin HM. et al. Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer. J Natl Cancer Inst 2014; 106: dju136 DOI: 10.1093/jnci/dju136. (PMID: 24895374)
• 88 Sparano JA, Gray R, Oktay MH. et al. A metastasis biomarker (MetaSite Breast Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer. NPJ Breast Cancer 2017; 3: 42 DOI: 10.1038/s41523-017-0043-5.
• 89 Karagiannis GS, Pastoriza JM, Wang Y. et al. Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. Sci Transl Med 2017; 9: eaan0026 DOI: 10.1126/scitranslmed.aan0026.
• 90 DeMichele A, Yee D, Esserman L. Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer. N Engl J Med 2017; 377: 2287-2289 DOI: 10.1056/NEJMcibr1711545. (PMID: 29211674)